帕金森病(PD)与癌症之间的关系一直存在争议。性别和遗传对PD癌症发展的影响尚不清楚。
使用QUOROM指南,我们对影响PD和随后的癌症关系的潜在临床和遗传因素进行了系统评价和荟萃分析.发表在PubMed上的英文文章,WebofScience,2010年至2020年8月30日的SCOPUS被认为是合适的。
在确定的46项研究中,14人符合纳入标准,并进行了进一步分析。计算未调整风险比(RR)和95%置信区间以确定PD和癌症的关系。PD患者随后的癌症风险降低(RR=0.87,95%CI=0.81-0.93),降低结肠风险,直肠,和结直肠癌(RR=0.77,95%CI=0.63-0.94),肺癌(RR=0.62,95%CI=0.48-0.80),和增加脑癌(R=1.48,95%CI=1.02-2.13)和黑色素瘤风险(R=1.76,95%CI=1.23-2.50)。与特发性PD相比,LRRK2-G2019S携带者的一般癌症风险增加(RR=1.26,95%CI=1.09-1.46),特别是大脑(RR=2.41,95%CI=1.06-5.50),乳房(RR=2.57,95%CI=1.19-5.58),结肠(RR=1.83,95%CI=1.13-2.99),和血液肿瘤(RR=2.05,95%CI=1.07-3.92)。在这项分析中,女性PD患者与男性PD患者相比,总体癌症风险降低(RR=0.83,95%CI=0.69-0.98)。
PD患者结肠风险降低,直肠,结直肠癌和肺癌以及脑癌和黑色素瘤的风险增加。LRRK2-G2019S携带者增加了癌症风险,尤其是大脑,乳房,结肠癌和血癌。女性与风险降低有关。种族的作用,合并症,和生活习惯对PD患者的后续癌症风险应进一步调查。
The relationship between Parkinson\'s disease (PD) and cancer has been debated. Gender and genetic influences on cancer development in PD is unclear.
Using QUOROM guidelines, we conducted a systematic
review and meta-analysis on potential clinical and genetic factors influencing the PD and subsequent cancer relationship. English articles published in PubMed, Web of Science, and SCOPUS from 2010 to 30 August 2020 were considered for suitability.
Of 46 studies identified, fourteen satisfied the inclusion criteria and were further analysed. Unadjusted risk ratios (RR) and 95% confidence intervals were computed to determine the PD and cancer relationship. PD patients have decreased subsequent cancer risks (RR = 0.87, 95% CI = 0.81-0.93), reduced risks of colon, rectal, and colorectal cancer (RR = 0.77, 95% CI = 0.63-0.94), lung cancer (RR = 0.62, 95% CI = 0.48-0.80), and increased brain cancer (R = 1.48, 95% CI = 1.02-2.13) and melanoma risk (R = 1.76, 95% CI = 1.23-2.50). Compared to idiopathic PD,
LRRK2-G2019S carriers had increased general cancer risks (RR = 1.26, 95% CI = 1.09-1.46), particularly brain (RR = 2.41, 95% CI = 1.06-5.50), breast (RR = 2.57, 95% CI = 1.19-5.58), colon (RR = 1.83, 95% CI = 1.13-2.99), and haematological cancers (RR = 2.05, 95% CI = 1.07-3.92). Female PD patients have decreased general cancer risks compared to male PD patients in this analysis (RR = 0.83, 95% CI = 0.69-0.98).
PD patients have reduced risks of colon, rectal, colorectal cancer and lung cancers and increased risks of brain cancer and melanoma.
LRRK2-G2019S carriers have increased cancer risks, particularly brain, breast, colon and blood cancers. Female gender was associated with reduced risks. The role of ethnicity, comorbidities, and lifestyle habits on PD patients\' subsequent cancer risk should be further investigated.